Adipocytokine levels in obese and non-obese subjects: An observational study

Inflammation

Volumn 36, Issue 4, 2013, Pages 914-920

  Derosa, Giuseppe ^a   Fogari, Elena ^a   D'Angelo, Angela ^a   Bianchi, Lucio ^a   Bonaventura, Aldo ^a   Romano, Davide ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

adipocytokines; adipose tissue; inflammation; insulin resistance; obesity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; COMPLEMENT FACTOR D; GLUCOSE; INSULIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; RETINOL BINDING PROTEIN 4; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASPIN;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; OBSERVATIONAL STUDY; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPOKINES; ADIPOSE TISSUE; ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; FEMALE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MALE; OBESITY; WAIST CIRCUMFERENCE;

EID: 84880310742     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-013-9620-4     Document Type: Article

References (57)

1. Van Gaal, L.F.; I.L. Mertens, and C.E. De Block. 2006. Mechanisms linking obesity with cardiovascular disease. Nature 444: 875-880.
2. Stevens, J.; J. Cai, E.R. Pamuk, D.F. Williamson, M.J. Thun, and J.L. Wood. 1998. The effect of age on the association between body-mass index and mortality. The New England Journal of Medicine 338(1): 1-7.
3. Laimer, M.; S. Kaser, M. Kranebitter, A. Sandhofer, G. Mühlmann, H. Schwelberger, H. Weiss, J.R. Patsch, and C.F. Ebenbichler. 2005. Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. International Journal of Obesity 29(5): 498-501.
4. Ahima, R.S. 2000. Leptin and the neuroendocrinology of fasting. Frontiers of Hormone Research 26: 42-56.
5. Flier, J.S. 2004. Obesity wars: molecular progress confronts an expanding epidemic. Cell 116(2): 337-350.
6. Hausman, G.J.; and R.L. Richardson. 2004. Adipose tissue angiogenesis. Journal of Animal Science 82(3): 925-934.
7. Rupnick, M.A.; D. Panigrahy, C.Y. Zhang, S.M. Dallabrida, B.B. Lowell, R. Langer, and M.J. Folkman. 2002. Adipose tissue mass can be regulated through the vasculature. Proceedings of the National Academy of Sciences of the United States of America 99(16): 10730-10735.
8. Trayhurn, P.; and I.S. Wood. 2004. Adipokines: inflammation and the pleiotropic role of white adipose tissue. British Journal of Nutrition 92(3): 347-355.
9. Weisberg, S.P.; D. McCann, M. Desai, M. Rosenbaum, R.L. Leibel, and A.W. Ferrante Jr. 2003. Obesity is associated with macrophage accumulation in adipose tissue. The Journal of Clinical Investigation 112(12): 1796-1808.
10. Derosa, G.; I. Ferrari, A. D'Angelo, C. Tinelli, S.A. Salvadeo, L. Ciccarelli, M.N. Piccinni, A. Gravina, F. Ramondetti, P. Maffioli, and A.F. Cicero. 2008. Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 15(4): 219-224.
11. Sluijter, J.P.; D.P. de Kleijn, and G. Pasterkamp. 2006. Vascular remodeling and protease inhibition - bench to bedside. Cardiovascular Research 69(3): 595-603.
12. World Health Organization. 1997. Obesity: preventing and managing the global epidemic. Report of WHO Consultation on Obesity. Geneva: WHO.
13. American Diabetes Association. 2001. Screening for diabetes (Position Statement). Diabetes Care 24: S21-S24.
14. European Diabetes Policy Group 1999. 1999. A desktop guide to type 2 diabetes mellitus. Diabetic Medicine 16(9): 716-730.
15. Heding, L.G. 1972. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 8(4): 260-266.
16. Matthews, D.R.; J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
17. Wallace, T.M.; J.C. Levy, and D.R. Matthews. 2004. Use and abuse of HOMA modeling. Diabetes Care 27: 1487-1495.
18. Klose, S.; and K. Borner. 1978. Enzymatische Bestimmung des Gesamtcholesterins mit dem [Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer (GSA II)]. Journal of Clinical Chemistry and Clinical Biochemistry 15: 121-130.
19. Wahlefeld, A.W. 1974. Triglycerides determination after enzymatic hydrolysis. In Methods of enzymatic analysis, 2 English edth ed, ed. H.U. Bergmeyer, 18-31. New York: Academic Press.
20. Havel, R.J.; H.A. Eder, and J.H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. The Journal of Clinical Investigation 34: 1345-1353.
21. Friedewald, W.T.; R.I. Levy, and D.S. Fredrickson. 1972. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18: 499-502.
22. Takebayashi, K.; M. Suetsugu, S. Wakabayashi, Y. Aso, and T. Inumai. 2007. Retinol binding protein-4 and clinical features of type 2 diabetes patients. Journal of Clinical Endocrinology and Metabolism 92: 2712-2719.
23. Hida, K.; J. Wada, J. Eguchi, H. Zhang, M. Baba, A. Seida, I. Hashimoto, T. Okada, A. Yasuhara, A. Nakatsuka, K. Shikata, S. Hourai, J. Futami, E. Watanabe, Y. Matsuki, R. Hiramatsu, S. Akagi, H. Makino, and Y.S. Kanwar. 2005. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proceedings of the National Academy of Sciences 102: 10610-10615.
24. De Souza Batista, C.M.; R.Z. Yang, M.J. Lee, N.M. Glynn, D.Z. Yu, J. Pray, K. Ndubuizu, S. Patil, A. Schwartz, M. Kligman, S.K. Fried, D.W. Gong, A.R. Shuldiner, T.I. Pollin, and J.C. McLenithan. 2007. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56(6): 1655-1661.
25. Song, M.; and J.A. Kellum. 2005. Interleukin-6. Critical Care Medicine 33(12): S463-S465.
26. Korner, A.; A. Garten, M. Bluher, R. Tauscher, J. Kratzsch, and W. Kiess. 2007. Molecular characteristics of serum visfatin and differential detection by immunoassays. Journal of Clinical Endocrinology and Metabolism 92: 4783-4791.
27. Yamauchi, T.; J. Kamon, H. Waki, Y. Terauchi, N. Kubota, K. Hara, Y. Mori, T. Ide, K. Murakami, N. Tsuboyama-Kasaoka, O. Ezaki, Y. Akanuma, O. Gavrilova, C. Vinson, M.L. Reitman, H. Kagechika, K. Shudo, M. Yoda, Y. Nakano, K. Tobe, R. Nagai, S. Kimura, M. Tomita, P. Froguel, and T. Kadowaki. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 7: 941-946.
28. Yannakoulia, M.; N. Yiannakouris, S. Bluher, A.L. Matalas, D. Klimis-Zacas, and C.S. Mantzoros. 2003. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. Journal of Clinical Endocrinology and Metabolism 88: 1730-1736.
29. Misra, A.; and A. Garg. 1996. Leptin: its receptor and obesity. Journal of Investigative Medicine 44: 540-548.
30. Cook, K.S.; D.L. Groves, H.Y. Min, and B.M. Spiegelman. 1985. Proceedings of the National Academy of Sciences of the United States of America 82: 6480-6484.
31. Zhang, M.; and K. Tracey. 1988. The cytokine handbook, 3rd ed. San Diego: Academic Press.
32. Rifai, N.; R.P. Tracy, and P.M. Ridker. 1999. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clinical Chemistry 45(12): 2136-2141.
33. Gu, P.; and A. Xu. 2013. Interplay between adipose tissue and blood vessels in obesity and vascular dysfunction. Reviews in Endocrine & Metabolic Disorders. doi: 10.1007/s11154-012-9230-8.
34. Yang, Q.; T.E. Graham, N. Mody, F. Preitner, O.D. Peroni, J.M. Zabolotny, K. Kotani, L. Quadro, and B.B. Kahn. 2005. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436(7049): 356-362.
35. Hida, K.; J. Wada, J. Eguchi, H. Zhang, M. Baba, A. Seida, I. Hashimoto, T. Okada, A. Yasuhara, A. Nakatsuka, K. Shikata, S. Hourai, J. Futami, E. Watanabe, Y. Matsuki, R. Hiramatsu, S. Akagi, H. Makino, and Y.S. Kanwar. 2005. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proceedings of the National Academy of Sciences of the United States of America 102(30): 10610-10615.
36. Youn, B.S.; N. Klöting, J. Kratzsch, N. Lee, J.W. Park, E.S. Song, K. Ruschke, A. Oberbach, M. Fasshauer, M. Stumvoll, and M. Blüher. 2008. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 57(2): 372-377.
37. El-Mesallamy, H.O.; D.H. Kassem, E. El-Demerdash, and A.I. Amin. 2011. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 60(1): 63-70.
38. Yang, R.Z.; M.J. Lee, H. Hu, J. Pray, H.B. Wu, B.C. Hansen, A.R. Shuldiner, S.K. Fried, J.C. McLenithan, and D.W. Gong. 2006. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. American Journal of Physiology, Endocrinology and Metabolism 290(6): E1253-E1261.
39. Schäffler, A.; M. Neumeier, H. Herfarth, A. Fürst, J. Schölmerich, and C. Büchler. 2005. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochimica et Biophysica Acta 1732(1-3): 96-102.
40. Kralisch, S.; J. Klein, M. Bluher, R. Paschke, M. Stumvoll, and M. Fasshauer. 2005. Therapeutic perspectives of adipocytokines. Expert Opinion on Pharmacotherapy 6: 863-872.
41. Fukuhara, A.; M. Matsuda, M. Nishizawa, K. Segawa, M. Tanaka, K. Kishimoto, Y. Matsuki, M. Murakami, T. Ichisaka, H. Murakami, E. Watanabe, T. Takagi, M. Akiyoshi, T. Ohtsubo, S. Kihara, S. Yamashita, M. Makishima, T. Funahashi, S. Yamanaka, R. Hiramatsu, Y. Matsuzawa, and I. Shimomura. 2005. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708): 426-430.
42. Hug, C.; and H.F. Lodish. 2005. Medicine. Visfatin: a new adipokine. Science 307(5708): 366-367.
43. Li, R.Z.; X.Y. Ma, X.F. Hu, S.X. Kang, S.K. Chen, K. Cianflone, and H.L. Lu. 2012. Elevated visfatin levels in obese children are related to proinflammatory factors. Journal of Pediatric Endocrinology & Metabolism 14: 1-8.
44. Olszanecka-Glinianowicz, M.; P. Kocełak, M. Nylec, J. Chudek, and B. Zahorska-Markiewicz. 2012. Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome. Archives of Medical Science 8(2): 214-218.
45. Azuma, K.; S. Oguchi, Y. Matsubara, T. Mamizuka, M. Murata, H. Kikuchi, K. Watanabe, F. Katsukawa, H. Yamazaki, A. Shimada, and T. Saruta. 2004. Novel resistin promoter polymorphisms: association with serum resistin level in Japanese obese individuals. Hormone and Metabolic Research 36(8): 564-570.
46. Bouchard, L.; S.J. Weisnagel, J.C. Engert, T.J. Hudson, C. Bouchard, M.C. Vohl, and L. Pérusse. 2004. Human resistin gene polymorphism is associated with visceral obesity and fasting and oral glucose stimulated C-peptide in the Québec Family Study. Journal of Endocrinological Investigation 27(11): 1003-1009.
47. McTernan, P.G.; F.M. Fisher, G. Valsamakis, R. Chetty, A. Harte, C.L. McTernan, P.M. Clark, S.A. Smith, A.H. Barnett, and S. Kumar. 2003. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. Journal of Clinical Endocrinology and Metabolism 88(12): 6098-6106.
48. Ohmori, R.; Y. Momiyama, R. Kato, H. Taniguchi, M. Ogura, M. Ayaori, H. Nakamura, and F. Ohsuzu. 2005. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. Journal of the American College of Cardiology 46(2): 379-380.
49. Jackson, M.B.; and R.S. Ahima. 2006. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clinical Science 110: 143-152.
50. Berg, A.H.; T.P. Combs, and P.E. Scherer. 2002. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends in Endocrinology and Metabolism 13: 84-89.
51. Bouskila, M.; U.B. Pajvani, and P.E. Scherer. 2005. Adiponectin: a relevant player in PPARγ-agonist mediated improvements in hepatic insulin sensitivity? International Journal of Obesity and Related Metabolic Disorders 29(Suppl. 1): S17-S23.
52. Maeda, N.; I. Shimomura, K. Kishida, H. Nishizawa, M. Matsuda, H. Nagaretani, N. Furuyama, H. Kondo, M. Takahashi, Y. Arita, R. Komuro, N. Ouchi, S. Kihara, Y. Tochino, K. Okutomi, M. Horie, S. Takeda, T. Aoyama, T. Funahashi, and Y. Matsuzawa. 2002. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nature Medicine 8: 731-737.
53. Berg, A.H.; T.P. Combs, X. Du, M. Brownlee, and P.E. Scherer. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Medicine 7: 947-953.
54. Cook, K.S.; H.Y. Min, D. Johnson, R.J. Chaplinsky, J.S. Flier, C.R. Hunt, and B.M. Spiegelman. 1987. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science 237(4813): 402-405.
55. Uysal, K.T.; S.M. Wiesbrock, M.W. Marino, and G.S. Hotamisligil. 1997. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389(6651): 610-614.
56. Hotamisligil, G.S.; N.S. Shargill, and B.M. Spiegelman. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259(5091): 87-91.
57. Hotamisligil, G.S. 1999. The role of TNF-alpha and TNF receptors in obesity and insulin resistance. Journal of Internal Medicine 245: 621-625.